“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Natalizumab Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice in Italy

(2017) R. Totaro et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Whole-brain atrophy

(2016) Christina J. Azevedo et al.   CURRENT OPINION IN NEUROLOGY

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene

(2016) Tom Massey et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis

(2016) Luca Prosperini et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Late Breaker News

(2016)   Multiple Sclerosis Journal

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

(2016) Tomas Uher et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

Late Breaker News

(2016)   Multiple Sclerosis Journal

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

(2016) Tomas Uher et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis

(2015) Timothy Vollmer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral presentations

(2015)   Multiple Sclerosis Journal

No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy

(2015) Alfredo Damasceno et al.   Multiple Sclerosis Journal

Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression

(2015) Marcello Moccia et al.   Multiple Sclerosis Journal

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

(2015) E.-W. Radue et al.   NEUROLOGY

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Oral presentations

(2015)   Multiple Sclerosis Journal

No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy

(2015) Alfredo Damasceno et al.   Multiple Sclerosis Journal

Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression

(2015) Marcello Moccia et al.   Multiple Sclerosis Journal

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

(2014) Richard Nixon et al.   ADVANCES IN THERAPY

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

(2014) Douglas L Arnold et al.   BMC Neurology

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

(2014) J Sastre-Garriga et al.   Multiple Sclerosis Journal

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

(2014) Jordi Río et al.   Multiple Sclerosis Journal

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

(2014) Martin Stangel et al.   Therapeutic Advances in Neurological Disorders

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

(2013) O. Outteryck et al.   EUROPEAN JOURNAL OF NEUROLOGY

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

(2013) Eva Havrdova et al.   Multiple Sclerosis Journal

Editors' welcome and a working definition for a multiple sclerosis cure

(2013) Brenda Banwell et al.   Multiple Sclerosis and Related Disorders

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

(2011) Luca Prosperini et al.   Multiple Sclerosis Journal

MRI predictors of cognitive outcome in early multiple sclerosis

(2011) M. S. A. Deloire et al.   NEUROLOGY

Disease activity free status in MS

(2011) Fred D. Lublin   Multiple Sclerosis and Related Disorders

Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis

(2010) Richard A. Rudick et al.   ARCHIVES OF NEUROLOGY

Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study

(2010) Maria P Amato et al.   Multiple Sclerosis Journal

Cognitive impairment in early stages of multiple sclerosis

(2010) Maria Pia Amato et al.   NEUROLOGICAL SCIENCES

Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis

(2009) Dana Horakova et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test

(2009) AS Drake et al.   Multiple Sclerosis Journal